{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:46:00Z","timestamp":1790837160457,"version":"4.1.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T00:00:00Z","timestamp":1545004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T00:00:00Z","timestamp":1545004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA201594"],"award-info":[{"award-number":["CA201594"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA076292-18S4"],"award-info":[{"award-number":["CA076292-18S4"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2019,2,1]]},"DOI":"10.1007\/s40259-018-0324-z","type":"journal-article","created":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T04:32:10Z","timestamp":1545021130000},"page":"45-60","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities"],"prefix":"10.1007","volume":"33","author":[{"given":"Bhagirathbhai R.","family":"Dholaria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina A.","family":"Bachmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9063-6691","authenticated-orcid":false,"given":"Frederick","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,17]]},"reference":[{"issue":"3","key":"324_CR1","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1042\/BST20160037","volume":"44","author":"CH Lamers","year":"2016","unstructured":"Lamers CH, Klaver Y, Gratama JW, Sleijfer S, Debets R. Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview. Biochem Soc Trans. 2016;44(3):951\u20139.","journal-title":"Biochem Soc Trans"},{"issue":"5","key":"324_CR2","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1084\/jem.181.5.1653","volume":"181","author":"T Brocker","year":"1995","unstructured":"Brocker T, Karjalainen K. Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes. J Exp Med. 1995;181(5):1653\u20139.","journal-title":"J Exp Med"},{"issue":"5","key":"324_CR3","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1172\/JCI46110","volume":"121","author":"B Savoldo","year":"2011","unstructured":"Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Investig. 2011;121(5):1822\u20136.","journal-title":"J Clin Investig"},{"key":"324_CR4","doi-asserted-by":"publisher","first-page":"16015","DOI":"10.1038\/mto.2016.15","volume":"3","author":"X Wang","year":"2016","unstructured":"Wang X, Riviere I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncolyt. 2016;3:16015.","journal-title":"Mol Ther Oncolyt"},{"issue":"280","key":"324_CR5","doi-asserted-by":"publisher","first-page":"280ps7","DOI":"10.1126\/scitranslmed.aaa3643","volume":"7","author":"CH June","year":"2015","unstructured":"June CH, Riddell SR, Schumacher TN. Adoptive cellular therapy: a race to the finish line. Sci Transl Med. 2015;7(280):280ps7.","journal-title":"Sci Transl Med."},{"issue":"26","key":"324_CR6","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"26","key":"324_CR7","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak O, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377(26):2545\u201354.","journal-title":"N Engl J Med"},{"key":"324_CR8","unstructured":"Borchmann P, Tam C, J\u00e4ger U, McGuirk J, Holte H, Waller E, et al. An updated analysis of JULIET, a global pivotal phase 2 trial of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma. European Hematology Association, abstract S799; June 2018."},{"key":"324_CR9","doi-asserted-by":"crossref","unstructured":"FDA approves second CAR T-cell therapy. Cancer Discov. 2018;8(1):5\u20136. http:\/\/cancerdiscovery.aacrjournals.org\/content\/8\/1\/5.full","DOI":"10.1158\/2159-8290.CD-NB2017-155"},{"issue":"10","key":"324_CR10","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2017.77.0446","volume":"36","author":"J Heymach","year":"2018","unstructured":"Heymach J, Krilov L, Alberg A, Baxter N, Chang SM, Corcoran R, et al. Clinical Cancer advances 2018: annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol. 2018;36(10):1020\u201344.","journal-title":"J Clin Oncol"},{"key":"324_CR11","unstructured":"First two CAR-T cell medicines recommended for approval in the European Union 2018. https:\/\/www.ema.europa.eu\/en\/news\/first-two-car-t-cell-medicines-recommended-approval-european-union. Accessed 19 Oct 2018."},{"key":"324_CR12","first-page":"19","volume":"Sep","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities. Nat Rev Clin Oncol. 2017;Sep:19.","journal-title":"Nat Rev Clin Oncol."},{"issue":"26","key":"324_CR13","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127(26):3321\u201330.","journal-title":"Blood"},{"issue":"2","key":"324_CR14","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188\u201395.","journal-title":"Blood"},{"issue":"6","key":"324_CR15","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24(6):731\u20138.","journal-title":"Nat Med"},{"issue":"6","key":"324_CR16","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24(6):739\u201348.","journal-title":"Nat Med"},{"key":"324_CR17","first-page":"18","volume":"Sep","author":"KA Hay","year":"2017","unstructured":"Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T cell therapy. Blood. 2017;Sep:18.","journal-title":"Blood"},{"issue":"7","key":"324_CR18","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nrd4597","volume":"14","author":"SJ van der Stegen","year":"2015","unstructured":"van der Stegen SJ, Hamieh M, Sadelain M. The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov. 2015;14(7):499\u2013509.","journal-title":"Nat Rev Drug Discov."},{"issue":"5","key":"324_CR19","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"issue":"16","key":"324_CR20","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507\u201317.","journal-title":"N Engl J Med"},{"issue":"6","key":"324_CR21","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR-T cells of defined CD4\u2009+\u2009:CD8\u2009+\u2009composition in adult B cell ALL patients. J Clin Investig. 2016;126(6):2123\u201338.","journal-title":"J Clin Investig"},{"key":"324_CR22","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","volume":"19;6(224)","author":"ML Davila","year":"2014","unstructured":"Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;19;6(224):224ra25.","journal-title":"Sci Transl Med."},{"key":"324_CR23","unstructured":"NCI Common Terminology Criteria for Adverse Events (CTCAE) v.4 data file. 2009; 4.0:[NCI]. http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed 13 Sept 2014."},{"key":"324_CR24","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017; https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf. Accessed 22 Apr 2018."},{"issue":"4","key":"324_CR25","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/nrclinonc.2018.20","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Locke FL, Lin Y, et al. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit \u2018ALL\u2019. Nat Rev Clin Oncol. 2018;15(4):218.","journal-title":"Nat Rev Clin Oncol."},{"key":"324_CR26","doi-asserted-by":"crossref","unstructured":"Porter DL, Hwang W-T, Frey NV, Lacey SF, Shaw PA, Loren AW, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7(303):303ra139\u2013303ra139.","DOI":"10.1126\/scitranslmed.aac5415"},{"issue":"1","key":"324_CR27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","volume":"11","author":"D Porter","year":"2018","unstructured":"Porter D, Frey N, Wood PA, Weng Y, Grupp SA. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol. 2018;11(1):35.","journal-title":"J Hematol Oncol."},{"key":"324_CR28","unstructured":"CAR-T toxicity rating system to be finalized by ASBMT by year-end\u2014Drug Development Technology. https:\/\/www.drugdevelopment-technology.com\/comment\/car-t-toxicity-rating-system-finalized-asbmt-year-end\/. Accessed 11 Sept 2018."},{"key":"324_CR29","unstructured":"Schuster SJBM, Tam CS. Primary analysis of JULIET: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma. Blood. 2017;130(suppl 1)."},{"issue":"1","key":"324_CR30","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12185-016-2039-6","volume":"104","author":"ML Davila","year":"2016","unstructured":"Davila ML, Sadelain M. Biology and clinical application of CAR T cells for B cell malignancies. Int J Hematol. 2016;104(1):6\u201317.","journal-title":"Int J Hematol"},{"key":"324_CR31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","volume":"Aug","author":"JN Brudno","year":"2017","unstructured":"Brudno JN, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol. 2017;Aug:31.","journal-title":"Nat Rev Clin Oncol."},{"key":"324_CR32","unstructured":"Center for Drug Evaluation and Research. Approved Drugs\u2014FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokine release syndrome. https:\/\/www.fda.gov\/drugs\/informationondrugs\/approveddrugs\/ucm574154.htm. Accessed 21 Nov 2018."},{"issue":"Suppl 1","key":"324_CR33","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1182\/blood.V130.Suppl_1.1547.1547","volume":"130","author":"FL Locke","year":"2017","unstructured":"Locke FL, Neelapu SS, Bartlett NL, Lekakis LJ, Jacobson CA, Braunschweig I, et al. Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) treatment for patients with refractory, aggressive non-hodgkin lymphoma (NHL). Blood. 2017;130(Suppl 1):1547.","journal-title":"Blood"},{"issue":"6","key":"324_CR34","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","volume":"6","author":"DT Teachey","year":"2016","unstructured":"Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016;6(6):664\u201379.","journal-title":"Cancer Discov"},{"issue":"9","key":"324_CR35","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/S1470-2045(14)70319-5","volume":"15","author":"F van Rhee","year":"2014","unstructured":"van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fossa A, et al. Siltuximab for multicentric Castleman\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014;15(9):966\u201374.","journal-title":"Lancet Oncol"},{"issue":"10","key":"324_CR36","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","volume":"112","author":"N Nishimoto","year":"2008","unstructured":"Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112(10):3959\u201364.","journal-title":"Blood"},{"issue":"177","key":"324_CR37","first-page":"177ra38","volume":"20","author":"RJ Brentjens","year":"2013","unstructured":"Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;20(177):177ra38.","journal-title":"Sci Transl Med."},{"issue":"4","key":"324_CR38","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/nrclinonc.2018.19","volume":"15","author":"DT Teachey","year":"2018","unstructured":"Teachey DT, Bishop MR, Maloney DG, Grupp SA. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol. 2018;15(4):218.","journal-title":"Nat Rev Clin Oncol."},{"issue":"12","key":"324_CR39","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7(12):1404\u201319.","journal-title":"Cancer Discov"},{"issue":"2","key":"324_CR40","first-page":"86","volume":"5","author":"D DeAngelo","year":"2017","unstructured":"DeAngelo D, Ghobadi A, Park J, Dinner S, Mannis G, Lunning M, et al. Clinical outcomes for the phase 2, single-arm, multicenter trial of JCAR015 in adult B-ALL (ROCKET Study). 32nd annual meeting and pre-conference programs of the Society for Immunotherapy of Cancer (SITC 2017): part one. J Immunother Cancer. 2017;5(2):86.","journal-title":"J Immunother Cancer."},{"key":"324_CR41","doi-asserted-by":"crossref","unstructured":"Santomasso B, Park JH, Riviere I, Mead E, Halton E, Diamonte C, et al. Biomarkers associated with neurotoxicity in adult patients with relapsed or refractory B-ALL (R\/R B-ALL) treated with CD19 CAR T cells. J Clin Oncol. 2017;35(15_suppl):3019.","DOI":"10.1200\/JCO.2017.35.15_suppl.3019"},{"issue":"1","key":"324_CR42","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47\u201362.","journal-title":"Nat Rev Clin Oncol."},{"issue":"5","key":"324_CR43","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Riviere I, Gonen M, Wang X, Senechal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449\u201359.","journal-title":"N Engl J Med"},{"key":"324_CR44","unstructured":"Package insert\u2014KYMRIAH. 2018. https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/CellularGeneTherapyProducts\/ApprovedProducts\/UCM573941.pdf. Accessed 1 May 2018."},{"key":"324_CR45","doi-asserted-by":"crossref","unstructured":"Abramson JS, Gordon LI, Palomba ML, Lunning MA, Arnason JE, Forero-Torres A, et al. Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R\/R aggressive NHL. J Clin Oncol. 2018;36(15_suppl):7505.","DOI":"10.1200\/JCO.2018.36.15_suppl.7505"},{"issue":"8","key":"324_CR46","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, et al. Clinical and biologic correlates of neurotoxicity associated with CAR T cell therapy in patients with B-cell Acute lymphoblastic leukemia (B-ALL). Cancer Discov. 2018;8(8):958\u201371.","journal-title":"Cancer Discov"},{"issue":"6","key":"324_CR47","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1158\/2159-8290.CD-17-1368","volume":"8","author":"A Taraseviciute","year":"2018","unstructured":"Taraseviciute A, Tkachev V, Ponce R, Turtle CJ, Snyder JM, Liggitt HD, et al. Chimeric antigen receptor T cell-mediated neurotoxicity in nonhuman primates. Cancer Discov. 2018;8(6):750\u201363.","journal-title":"Cancer Discov"},{"issue":"21","key":"324_CR48","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017;130(21):2295\u2013306.","journal-title":"Blood"},{"key":"324_CR49","doi-asserted-by":"publisher","first-page":"358ra128","DOI":"10.1126\/scitranslmed.aaf6812","volume":"28;8(358)","author":"SJ Higgins","year":"2016","unstructured":"Higgins SJ, Purcell LA, Silver KL, Tran V, Crowley V, Hawkes M, et al. Dysregulation of angiopoietin-1 plays a mechanistic role in the pathogenesis of cerebral malaria. Sci Transl Med. 2016;28;8(358):358ra128.","journal-title":"Sci Transl Med."},{"issue":"16","key":"324_CR50","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","volume":"35","author":"JN Kochenderfer","year":"2017","unstructured":"Kochenderfer JN, Somerville RPT, Lu T, Shi V, Bot A, Rossi J, et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J Clin Oncol. 2017;35(16):1803\u201313.","journal-title":"J Clin Oncol"},{"key":"324_CR51","doi-asserted-by":"crossref","unstructured":"Turtle CJ, Hay KA, Juliane G, Hanafi L-A, Li D, Chaney C, et al. Biomarkers of Cytokine Release Syndrome and Neurotoxicity after CD19 CAR-T cells and mitigation of toxicity by cell dose. Blood. 2016;128(22):1852.","DOI":"10.1182\/blood.V128.22.1852.1852"},{"issue":"9967","key":"324_CR52","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet (London, England). 2015;385(9967):517\u201328.","journal-title":"Lancet (London, England)."},{"issue":"1","key":"324_CR53","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13045-016-0299-5","volume":"9","author":"Y Hu","year":"2016","unstructured":"Hu Y, Sun J, Wu Z, Yu J, Cui Q, Pu C, et al. Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy. J Hematol Oncol Engl. 2016;9(1):70.","journal-title":"J Hematol Oncol Engl."},{"issue":"4","key":"324_CR54","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1017\/S147895151600095X","volume":"15","author":"V Prudent","year":"2017","unstructured":"Prudent V, Breitbart WS. Chimeric antigen receptor T-cell neuropsychiatric toxicity in acute lymphoblastic leukemia. Palliat Support Care. 2017;15(4):499\u2013503.","journal-title":"Palliat Support Care."},{"key":"324_CR55","doi-asserted-by":"crossref","unstructured":"Raje NS, Berdeja JG, Lin Y, Munshi N, Siegel BA, Liedtke M, et al. bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed\/refractory multiple myeloma: Updated results from a multicenter phase I study. J Clin Oncol. 2018;36(suppl; abstr 8007).","DOI":"10.1200\/JCO.2018.36.15_suppl.8007"},{"issue":"4","key":"324_CR56","first-page":"209","volume":"13","author":"VC Pangman","year":"2000","unstructured":"Pangman VC, Sloan J, Guse L. An examination of psychometric properties of the mini-mental state examination and the standardized mini-mental state examination: implications for clinical practice. ANR. 2000;13(4):209\u201313.","journal-title":"ANR."},{"issue":"7872","key":"324_CR57","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0140-6736(74)91639-0","volume":"2","author":"G Teasdale","year":"1974","unstructured":"Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet (London, England). 1974;2(7872):81\u20134.","journal-title":"Lancet (London, England)"},{"issue":"Suppl 1","key":"324_CR58","first-page":"505","volume":"130","author":"AD Cohen","year":"2017","unstructured":"Cohen AD, Garfall AL, Stadtmauer EA, Lacey SF, Lancaster E, Vogl DT, et al. Safety and efficacy of B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) with cyclophosphamide conditioning for refractory multiple myeloma (MM). Blood. 2017;130(Suppl 1):505.","journal-title":"Blood"},{"key":"324_CR59","doi-asserted-by":"crossref","unstructured":"Locke F, Ghobadi A, Lekakis LJ, Miklos DB, Jacobson CA, Jacobsen ED, et al. Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B cell lymphoma. J Clin Oncol. 2018;36(no. 15_suppl):3039.","DOI":"10.1200\/JCO.2018.36.15_suppl.3039"},{"issue":"1","key":"324_CR60","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","volume":"25","author":"FL Locke","year":"2017","unstructured":"Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther. 2017;25(1):285\u201395.","journal-title":"Mol Ther"},{"key":"324_CR61","doi-asserted-by":"crossref","unstructured":"Gardner R, Leger KJ, Annesley CE, Summers C, Rivers J, Gust J, et al. Decreased rates of severe CRS seen with early intervention strategies for CD19 CAR-T cell toxicity management. Blood. 2016;128(22):586.","DOI":"10.1182\/blood.V128.22.586.586"},{"key":"324_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2016.03.005","volume":"434","author":"F Chen","year":"2016","unstructured":"Chen F, Teachey DT, Pequignot E, Frey N, Porter D, Maude SL, et al. Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and\/or siltuximab following CAR T cell therapy. J Immunol Methods. 2016;434:1\u20138.","journal-title":"J Immunol Methods"},{"key":"324_CR63","doi-asserted-by":"crossref","unstructured":"Park JH, Santomasso B, Riviere I, Senechal B, Wang X, Purdon T, et al. Baseline and early post-treatment clinical and laboratory factors associated with severe neurotoxicity following 19-28z CAR T cells in adult patients with relapsed B-ALL. J Clin Oncol. 2017;35(15_suppl):7024.","DOI":"10.1200\/JCO.2017.35.15_suppl.7024"},{"issue":"Suppl 1","key":"324_CR64","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1182\/blood.V130.Suppl_1.806.806","volume":"130","author":"S Ghorashian","year":"2017","unstructured":"Ghorashian S, Kramer AM, Albon SJ, Wright G, Castro F, Popova B, et al. A Novel Low affinity CD19CAR results in durable disease remissions and prolonged CAR T cell persistence without severe CRS or neurotoxicity in patients with paediatric ALL. Blood. 2017;130(Suppl 1):806.","journal-title":"Blood"},{"key":"324_CR65","doi-asserted-by":"crossref","unstructured":"Watanabe K, Terakura S, Uchiyama S, Martens AC, Meerten TV, Kiyoi H, et al. Excessively high-affinity single-chain fragment variable region in a chimeric antigen receptor can counteract T-cell proliferation. Blood. 2014;124(21):4799.","DOI":"10.1182\/blood.V124.21.4799.4799"},{"issue":"1","key":"324_CR66","doi-asserted-by":"publisher","first-page":"14366","DOI":"10.1038\/s41598-017-14749-3","volume":"7","author":"S Park","year":"2017","unstructured":"Park S, Shevlin E, Vedvyas Y, Zaman M, Hsu YS, Min IM, et al. Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity. Sci Rep. 2017;7(1):14366.","journal-title":"Sci Rep."},{"issue":"9","key":"324_CR67","doi-asserted-by":"publisher","first-page":"4936","DOI":"10.4049\/jimmunol.1000173","volume":"184","author":"DA Schmid","year":"2010","unstructured":"Schmid DA, Irving MB, Posevitz V, Hebeisen M, Posevitz-Fejfar A, Sarria JC, et al. Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J Immunol. 2010;184(9):4936\u201346.","journal-title":"J Immunol."},{"issue":"17","key":"324_CR68","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1158\/0008-5472.CAN-15-0139","volume":"75","author":"HG Caruso","year":"2015","unstructured":"Caruso HG, Hurton LV, Najjar A, Rushworth D, Ang S, Olivares S, et al. Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent anti-tumor activity. Cancer Res. 2015;75(17):3505\u201318.","journal-title":"Cancer Res"},{"issue":"7643","key":"324_CR69","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJ, Hamieh M, Cunanan KM, et al. Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature. 2017;543(7643):113\u20137.","journal-title":"Nature"},{"issue":"7","key":"324_CR70","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/s41591-018-0050-6","volume":"24","author":"RJ Ihry","year":"2018","unstructured":"Ihry RJ, Worringer KA, Salick MR, Frias E, Ho D, Theriault K, et al. p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells. Nat Med. 2018;24(7):939\u201346.","journal-title":"Nat Med"},{"issue":"11","key":"324_CR71","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.exphem.2016.07.011","volume":"44","author":"X Zhou","year":"2016","unstructured":"Zhou X, Brenner MK. Improving the safety of T-Cell therapies using an inducible caspase-9 gene. Exp Hematol. 2016;44(11):1013\u20139.","journal-title":"Exp Hematol"},{"key":"324_CR72","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3389\/fimmu.2018.00507","volume":"9","author":"M Casucci","year":"2018","unstructured":"Casucci M, Falcone L, Camisa B, Norelli M, Porcellini S, Stornaiuolo A, et al. Extracellular NGFR spacers allow efficient tracking and enrichment of fully functional CAR-T cells co-expressing a suicide gene. Front Immunol. 2018;9:507.","journal-title":"Front Immunol"},{"issue":"12","key":"324_CR73","doi-asserted-by":"publisher","first-page":"e0166891","DOI":"10.1371\/journal.pone.0166891","volume":"11","author":"K Minagawa","year":"2016","unstructured":"Minagawa K, Jamil MO, Al-Obaidi M, Pereboeva L, Salzman D, Erba HP, et al. In vitro pre-clinical validation of suicide gene modified anti-CD33 redirected chimeric antigen receptor T-cells for acute myeloid leukemia. PLoS One. 2016;11(12):e0166891.","journal-title":"PLoS One"},{"issue":"17","key":"324_CR74","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1182\/blood-2016-08-736041","volume":"129","author":"SK Tasian","year":"2017","unstructured":"Tasian SK, Kenderian SS, Shen F, Ruella M, Shestova O, Kozlowski M, et al. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia. Blood. 2017;129(17):2395\u2013407.","journal-title":"Blood"},{"issue":"Suppl 1","key":"324_CR75","first-page":"1271","volume":"130","author":"W Qasim","year":"2017","unstructured":"Qasim W, Ciocarlie O, Adams S, Inglott S, Murphy C, Rivat C, et al. Preliminary results of UCART19, an allogeneic anti-CD19 CAR T-cell product in a first-in-human trial (PALL) in pediatric patients with CD19\u2009+\u2009relapsed\/refractory B-cell acute lymphoblastic leukemia. Blood. 2017;130(Suppl 1):1271.","journal-title":"Blood"},{"issue":"8","key":"324_CR76","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1158\/2326-6066.CIR-16-0043","volume":"4","author":"R Sakemura","year":"2016","unstructured":"Sakemura R, Terakura S, Watanabe K, Julamanee J, Takagi E, Miyao K, et al. A tet-on inducible system for controlling CD19-chimeric antigen receptor expression upon drug administration. Cancer Immunol Res. 2016;4(8):658\u201368.","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"324_CR77","doi-asserted-by":"publisher","first-page":"E450","DOI":"10.1073\/pnas.1524193113","volume":"113","author":"JS Ma","year":"2016","unstructured":"Ma JS, Kim JY, Kazane SA, Choi SH, Yun HY, Kim MS, et al. Versatile strategy for controlling the specificity and activity of engineered T cells. Proc Natl Acad Sci USA. 2016;113(4):E450\u20138.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"7","key":"324_CR78","doi-asserted-by":"publisher","first-page":"39833","DOI":"10.1038\/srep39833","volume":"20","author":"A Juillerat","year":"2017","unstructured":"Juillerat A, Marechal A, Filhol JM, Valogne Y, Valton J, Duclert A, et al. An oxygen sensitive self-decision making engineered CAR T-cell. Sci Rep. 2017;20(7):39833.","journal-title":"Sci Rep."},{"issue":"4","key":"324_CR79","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","volume":"164","author":"KT Roybal","year":"2016","unstructured":"Roybal KT, Rupp LJ, Morsut L, Walker WJ, McNally KA, Park JS, et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell. 2016;164(4):770\u20139.","journal-title":"Cell"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-018-0324-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-018-0324-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-018-0324-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T07:06:54Z","timestamp":1744700814000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-018-0324-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,17]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2,1]]}},"alternative-id":["324"],"URL":"https:\/\/doi.org\/10.1007\/s40259-018-0324-z","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,17]]},"assertion":[{"value":"17 December 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This work was supported by an NCI K23 award (PI- Locke, F; CA201594, NIH\/NCI) and an NCI Cancer Center support grant P30 (CA076292-18S4, NIH\/NCI). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Frederick Locke declares being a scientific advisor to Kite (a Gilead subsidiary) and Novartis; and a consultant for Cellular BioMedicine Group. Bhagirathbhai R. Dholaria and Christina Bachmeier declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}